Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Clin Cancer Res. 2018 Apr 24;24(15):3656–3667. doi: 10.1158/1078-0432.CCR-17-3457

Figure 3. Therapeutic activity of AAZ+-ValCit-MMAE in combination with the immuno-cytokine L19-IL2 in BALB/c nu/nu mice bearing SKRC-52 renal cell carcinoma.

Figure 3

Nude mice bearing established subcutaneous tumors were treated with AAZ+-ValCit-MMAE (compound 2; 250 nmol/kg; IV; black arrow) and L19-IL2 (2.5 mg/Kg; IV; white arrow), as monotherapy or in a combination regimen. Graph (A) compares the therapeutic activity of the different treatment. Data points represent mean tumor volume ± SEM, n = 5 per group. CR = Complete Responses. In graph (B) percentage changes of body weight during the experiment are represented. **** indicates p<0.0001; *** indicates p<0.001; ** indicates p<0.01 (2-way ANOVA test, followed by Bonferroni post-test).